SCHEMBL1480293

SCHEMBL1480293

Clc1ccc(-c2c[nH]c(C=Cc3ccc4cc(OCc5ccccc5)ccc4c3)n2)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.52
LCK P06239 1/20 0.44
KCNA3 P22001 2/20 0.43
ALOX5 P09917 1/20 0.41
CNR1 P21554 6/20 0.38
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP1A1 P04798 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP19A1 P11511 1/20 0.36
HPGD P15428 1/20 0.36
PTPN1 P18031 1/20 0.36
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CCNB2 O95067 1/20 0.35
CDK1 P06493 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480292 1.00 BACE1 (0.52) BACE1LCKKCNA3ALOX5CNR1
SCHEMBL1480403 0.94 BACE1 (0.51) BACE1LCKKCNA3ALOX5CNR1
SCHEMBL1480400 0.94 BACE1 (0.51) BACE1LCKKCNA3ALOX5CNR1
SCHEMBL1480854 0.91 BACE1 (0.51) BACE1LCKKCNA3ALOX5CNR1
SCHEMBL1480851 0.91 BACE1 (0.51) BACE1LCKKCNA3ALOX5CNR1
SCHEMBL1480844 0.85 RELA (0.41) BACE1HPGDALDH1A1NPSR1
SCHEMBL1480848 0.85 RELA (0.41) BACE1HPGDALDH1A1NPSR1
SCHEMBL1481226 0.84 ATP4A (0.41) BACE1CNR1ALDH1A1L3MBTL1
SCHEMBL1481224 0.84 ATP4A (0.41) BACE1CNR1ALDH1A1L3MBTL1
SCHEMBL1483642 0.82 RELA (0.41) BACE1ALOX5HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ BACE1 4200/4885LCK 92/4885KCNA3 3092/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ BACE1 4200/4885LCK 92/4885KCNA3 3092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.